Astellas Pharma Inc (ALPMY) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Astellas Pharma Inc stock $22.12, price $15.82, upside +39.8%, quality 76 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $8.27 – $16.49 · fair‑value band $16.62 – $27.62 · the $15.82 price screens below the $22.12 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Astellas Pharma in your weekly email
Every Wednesday you see whether Astellas Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally.
Show moreShow less
The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer.
It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant.
It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution.
It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005.
Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Stock analysis
Astellas Pharma Inc (ALPMY) currently trades at $15.82, while our model-based Fair Value estimate is $22.12, implying the stock looks roughly 28% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $31.56 per share, and 18 of the 26 models we run sit above the $15.82 price.
Bear case: the Dividend Discount group reads lowest at $10.07, and 8 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: $16.62 (bear) to $27.62 (bull), the price of $15.82 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Astellas Pharma Inc reported revenue of ¥2.3T in FY2026 versus ¥1.3T in FY2022, a compound +15.0%/yr. Reported net income was ¥309B in FY2026, compounding +25.6%/yr from FY2022.
Key figures
Market cap $28.4B Large · P/E ratio 12.0 · P/S ratio 1.63 · EPS (TTM) $1.32 · Dividend yield 3.1% · Net margin 13.6% · Return on equity 21.3% · Return on assets (EBIT) 6.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 75 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 40%, ALPMY screens cheaper than that median.
Fair Value models
Bear$16.62Fair Value $22.12Bull$27.62
Price $15.82 · Upside +39.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($0.5053 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.97/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+18.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Start year 2021 (pandemic). Over 10 years: +5.2% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in JPY (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−5.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.7%
Dividend (yield on the price)3.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.20.7% vs 6.7%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 20%
2026 sits 510% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−8.9%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−3.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about −10.8% a year for the price and −5.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
AI conclusion: Limited public signals and modest profitability metrics constrain the assessment, yet the oncology pipeline with protein degraders and PADCEV combinations forms the main strength.
Main risk: Generic versions of XTANDI from competitors could enter after US patent expiry in 2027 and erode sales and margins on this key prostate cancer product.
Bull case: Astellas could accelerate its pipeline of strategic brands like PADCEV and new degraders through AI-enhanced discovery and partnerships to offset any XTANDI revenue decline.
Bear case: If generics and price cuts hit XTANDI hard without sufficient new product launches, overall revenues could decline sharply and pressure the company's oncology-focused growth strategy.
Astellas is moving its KRAS G12D-targeted protein degrader setidegrasib into a Phase 3 trial for previously treated advanced non-small cell lung cancer while gearing up for long-term follow-up data on PADCEV combinations at ESMO. This builds on its oncology focus amid efforts to optimize costs over the next five years. Our models see it as undervalued. Will the new degradation technology drive pipeline-led growth faster than maturing products like XTANDI slow it down?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score76 · Top 25%
Fair Value upside+39.8% · Top 25%
Profitability
Return on equity (12 months)21.3% · Top 25%
Return on assets8.6% · Above median
Net margin (12 months)16.1% · Above median
Operating margin (12 months)28.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)26.7% · Top 25%
Dividend yield (12 months)3.1% · Above median
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Astellas Pharma Inc (ALPMY) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $22.12 versus a price of $15.82, about +40% upside (undervalued).
What is the fair value of ALPMY?
Our model-based fair value for Astellas Pharma Inc is $22.12 (as of Nov 9, 2026), built from audited fundamentals. The current price: $15.82.
What is the quality score of ALPMY?
Astellas Pharma Inc has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Astellas Pharma Inc (ALPMY)?
Our model-based price target is the fair value of $22.12 (as of Nov 9, 2026) from 26 valuation models. Cautious scenario $16.62, optimistic scenario $27.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Astellas Pharma Inc stock forecast for 2026?
Our models put fair value at $22.12, about +40% upside versus a price of $15.82 (undervalued). Cautious scenario $16.62, optimistic scenario $27.62. The calculation is refreshed regularly with new filings.
What is the revenue of Astellas Pharma Inc (ALPMY)?
Astellas Pharma Inc reported trailing-twelve-month revenue of about ¥2.3T (latest available figure, as of Nov 9, 2026).
Does Astellas Pharma Inc pay a dividend?
Astellas Pharma Inc currently shows a dividend yield of 3.12% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Astellas Pharma Inc (ALPMY) and when is the ex-dividend date?
Astellas Pharma Inc pays a dividend of $0.493 per share a year, a dividend yield of 3.1%. The last ex-dividend date was Mar 31, 2026. A dividend has been paid every year since at least 2009. The payout ratio is 45.2% of earnings. Free cash flow covers the dividend 3.86 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Astellas Pharma Inc (ALPMY)?
For today's price to be fair in a discounted-cash-flow model, Astellas Pharma Inc would have to grow free cash flow by -8.9 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.7 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of ALPMY use?
Our models discount Astellas Pharma Inc at 8.1 %: a base by market capitalisation (large), damped by beta 0.09, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Astellas Pharma Inc that is -8.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Astellas Pharma Inc (ALPMY) delivered so far?
Over the past 5 years revenue at Astellas Pharma Inc grew +12.7 % a year. The price currently implies free-cash-flow growth of -8.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Astellas Pharma Inc (ALPMY) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Astellas Pharma Inc (-8.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Astellas Pharma Inc (ALPMY)?
The free-cash-flow yield on the price is 11.98 %: that much free cash flow Astellas Pharma Inc produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Astellas Pharma Inc (ALPMY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Astellas Pharma Inc it is $22.12 per share (as of Nov 9, 2026), against a price of $15.82. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Astellas Pharma Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, ALPMY trades below its calculated fair value: price $15.82, fair value $22.12, a gap of about +40% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALPMY?
No. The price is what the market pays today ($15.82); the fair value is what the company's own numbers justify ($22.12). For Astellas Pharma Inc the two are $6.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Astellas Pharma Inc worth?
The market values Astellas Pharma Inc at about $28.4B (market capitalisation, as of Nov 9, 2026). Per share that is $15.82; our models calculate a fair value of $22.12 per share.
What do the bullish and bearish scenarios say about ALPMY?
Our models span a range for Astellas Pharma Inc: cautious scenario $16.62, base $22.12, optimistic $27.62 per share (as of Nov 9, 2026, price $15.82). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALPMY?
Astellas Pharma Inc trades at a price-to-earnings ratio of 12.0 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $22.12 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 23.1. Other multiples: P/B 2.5, P/S 2.0, EV/EBITDA 6.8.
How solid is the balance sheet of Astellas Pharma Inc (ALPMY)?
Balance-sheet figures for Astellas Pharma Inc (as of Nov 9, 2026): return on equity 21.3%, debt of 0.17 per unit of equity. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is ALPMY from its 52-week high?
Astellas Pharma Inc trades at $15.82, about 4% below its 52-week high of $16.49 and 47% above the low of $10.76 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $22.12 is for.
Which stocks are comparable to Astellas Pharma Inc?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Astellas Pharma Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $15.82, calculated fair value $22.12 (+40%), Quality Score 76/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALPMY calculated?
We run Astellas Pharma Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $22.12 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Astellas Pharma Inc currently trades 28% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Astellas Pharma Inc (ALPMY)?
The closing price on Nov 6, 2026 was $15.82. Our model-based fair value is $22.12, about +40% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Astellas Pharma Inc right now?
The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($16.62). The market is more pessimistic than our downside scenario.
Where does the earnings growth of Astellas Pharma Inc (ALPMY) come from?
Earnings per share at Astellas Pharma Inc grew −2.1 % a year from 2015 to 2026. Broken into its drivers: revenue per share +6.5 %, EBIT margin −8.5 %, tax rate +1.1 %, residual (interest, one-offs) −0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Astellas Pharma Inc
How large is the market capitalisation of Astellas Pharma Inc (ALPMY)?
The market capitalisation of Astellas Pharma Inc is $28.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Astellas Pharma Inc (ALPMY)?
The price-to-sales ratio of Astellas Pharma Inc is 1.63 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Astellas Pharma Inc (ALPMY)?
Earnings per share at Astellas Pharma Inc are $1.32 (price ÷ EPS = P/E 12.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Astellas Pharma Inc (ALPMY)?
The dividend yield of Astellas Pharma Inc is 3.1% (payout 37.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Astellas Pharma Inc (ALPMY)?
The net margin of Astellas Pharma Inc is 13.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Astellas Pharma Inc (ALPMY)?
The return on equity (ROE) of Astellas Pharma Inc is 21.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Astellas Pharma Inc (ALPMY)?
On an EBIT basis the return on assets of Astellas Pharma Inc is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Astellas Pharma Inc (ALPMY)?
The operating margin of Astellas Pharma Inc is 28.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Astellas Pharma Inc (ALPMY)?
Revenue at Astellas Pharma Inc is growing +26.7% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Astellas Pharma Inc (ALPMY)?
Earnings per share at Astellas Pharma Inc are growing +107% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Astellas Pharma Inc (ALPMY) hold?
Astellas Pharma Inc holds more cash than debt, ¥35.8B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Astellas Pharma Inc in the live analysis
One click puts Astellas Pharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026